Search company, investor...

Compare Cell Therapeutics vs Poniard Pharmaceuticals

Customers evaluate the quality of Cell Therapeutics's products using the following success metrics.

Overview

Cell Therapeutics is 33 yrs old and is based in United States.

CTI is committed to developing, acquiring, and commercializing innovative treatments for cancer. In the company's pursuit of making cancer more treatable, they are developing a diversified portfolio of oncology products focused on identifying and developing new, less toxic, and more effective ways to treat cancer.

Poniard Pharmaceuticals is 40 yrs old and is based in United States.

Poniard Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration resistant prostate cancers (also known as hormone refractory prostate cancer), as well as a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

Country

United States

Demo Video

Demo not available because Cell Therapeutics has not claimed their profile.

Work for Cell Therapeutics? Show off your product.

Demo not available because Poniard Pharmaceuticals has not claimed their profile.

Work for Poniard Pharmaceuticals? Show off your product.

Leadership

Craig W. Philips (President)

See all 5 people

Ronald Martell (Chief Operating Officer)

See all 5 people

Funding

Cell Therapeutics last raised $40M on 2/15/2000.
Poniard Pharmaceuticals last raised $61.57M on 4/18/2006.

Stage

Unattributed VC - II

Investors

EW Healthcare Partners, ProQuest Investments

See all 5 investors

TD Asset Management, Highbridge Capital Management

See all 5 investors

Product

Benefits

Products

Customers

Known Partners

Why They Buy

Information not available because Cell Therapeutics has not claimed their profile.

Work for Cell Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for Cell Therapeutics?

Claim your profile now.

Information not available because Poniard Pharmaceuticals has not claimed their profile.

Work for Poniard Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for Poniard Pharmaceuticals?

Claim your profile now.